Skip to main content

Advertisement

SpringerLink
Log in

Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Studies determining the association between hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and bone metabolism are mixed. We conducted a systematic review to assess the potential impact of statins on fractures, bone mineral density and bone markers. We searched Medline, Embase, the Cochrane Library, and Federal Research in Progress (FEDRIP). Inclusion criteria consisted of human studies with measurable outcomes, which were rated as good or fair according to the United States Preventive Services Task Force (USPSTF) criteria. The effects of statins on bone mineral density (BMD), bone markers and fracture risk were independently extracted by two reviewers and were combined by use of a random-effects model. The 31 analyzed studies included 24 observational studies and seven randomized controlled trials. Overall, statin use was associated with fewer hip fractures (OR 0.60, 95% CI 0.45–0.78) and improved hip BMD (Z score 0.12, 95% CI 0.05–0.19), with a non-significant reduction in vertebral fractures and no effect on vertebral BMD. In subgroup analysis of studies that involved only women there was a reduction in hip fractures (OR 0.75, 95% CI 0.60–0.95) and improvement in hip BMD (Z score 0.11, 95% CI 0.04–0.18). Vertebral BMD was unchanged, and only one study reported on vertebral fractures, finding improvement. Statins had only small effects on bone markers, with a decrease in alkaline phosphatase [standardized mean difference (SMD) −0.18, 95% CI −0.34 to −0.01], an increase in NTX (SMD 0.39, 95% CI 0.07–0.71), with no effect on osteocalcin or CTX. The statistically significant improvement in hip fracture risk was seen only in case–control trials, not in either the eight prospective trials or the two randomized controlled trials (RCTs). Statins may have a beneficial impact on bone metabolism and fracture risk; randomized controlled trials are needed to explore this association.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ansell BJ, Watson KE, Weiss RE, Fonarow GC (2003) CRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis 5:2–7)

    Article  CAS  PubMed  Google Scholar 

  2. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL (2003) Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 107:258–263

    Google Scholar 

  3. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH (2002) Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation106:1447–1452

  4. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, Kim DS, Jeong EM, Park GS, Choi IS, Shin EK (2002) Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22:e19–23

    Article  PubMed  Google Scholar 

  5. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J (2002) Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89:901–908

    Article  CAS  PubMed  Google Scholar 

  6. Mundy G, Garret R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949

    Article  CAS  PubMed  Google Scholar 

  7. Bauer DC (2003) HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 14:273–282

    Article  CAS  PubMed  Google Scholar 

  8. Luckman SP, Hughes DE, Coxon FP (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational phenylation of GTP-binding proteins, including ras. J Bone Miner Res 13:581–589

    CAS  PubMed  Google Scholar 

  9. Woo J, Kasai S, Stern P, Nagai K (2000) Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 15:650–658

    CAS  PubMed  Google Scholar 

  10. Harris RP, Helfand M, Woolf SH, et al (2001) Current methods of the US preventive services task force. A review of the process. Am J Prev Med 20:21–35

    Article  CAS  Google Scholar 

  11. Follman D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45:769–773

    Google Scholar 

  12. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    CAS  PubMed  Google Scholar 

  13. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463

    Article  PubMed  Google Scholar 

  14. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894

    CAS  PubMed  Google Scholar 

  15. Mantel N, Haenszel W Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 29:719–748

  16. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials. 7:177–188

    Google Scholar 

  17. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18:2693–2708

    Article  CAS  PubMed  Google Scholar 

  18. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137–1142

    Google Scholar 

  19. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218–2219

    Article  CAS  PubMed  Google Scholar 

  20. Van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850–1855

    Article  PubMed  Google Scholar 

  21. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211–3216

    Article  CAS  PubMed  Google Scholar 

  22. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205–3210

    Article  CAS  PubMed  Google Scholar 

  23. Rejnmark L, Olson ML, Johnsen SP, Vestorgaar P, Sorenson HT, Mosekilde L (2004) Hip fracture risk in statin users: a population based, Danish case–control study. Osteoporos Int 15:452–458

    PubMed  Google Scholar 

  24. Chan KA, Andrade SE, Boles M, et al (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188

    Article  CAS  PubMed  Google Scholar 

  25. Barengolts E, Karanouh D, Kolodny L, Kukreja S (2001) Risk factors for hip fractures in predominantly African–American veteran male population. J Bone Miner Res 16 [Suppl 1]:S170

  26. Sirola J, Honkanen R, Kroger H, et al (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537–541

    Article  CAS  PubMed  Google Scholar 

  27. Cauley JA, Jackson R, Pettinger M, et al (2000) Statin use and bone mineral density in older women: the women’s health initiative observational study (WHI-OS). J Bone Miner Res 15 [Suppl]:1068

  28. Bauer DC, Mundy GR, Jamal SA, et al (1999) Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res 14 [Suppl]:1188

  29. LaCroix AZ, Cauley JA, Jackson R, et al (2000) Does statin use reduce risk of fracture in postmenopausal women? Results from the women’s health initiative observational study. J Bone Miner Res 15 [Suppl]:1066

  30. Mostaza JM, Concepcion De la Piedra, et al (2001) Pravastatin therapy increases procollagen I n-terminal propeptide (pinp), a marker of bone formation in post-menopausal women. Clin Chim Acta 308:133–137

    Article  CAS  PubMed  Google Scholar 

  31. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud K, van der Dlift M, Pols HAP (2004) Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146–152

    Article  CAS  PubMed  Google Scholar 

  32. Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, Lucani B, Gennari C (2003) Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 23:427–433

    Article  Google Scholar 

  33. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley G, Passaro MD, Jackson RD (2003) Statin use, clinical fracture and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study. Ann Intern Med 139:97–104

    CAS  PubMed  Google Scholar 

  34. Lupattelli G, Scarpon AM, Donatella GV, Siepi D, Roscini AR, Gemelli F, Pirro M, Latini RA, Sinzinger H, Marchesi S, Mannarino E (2004) Metabolism. 53:744–748

  35. Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865

    Article  CAS  Google Scholar 

  36. Funkhouser HL, Tilahun A, Adler RA (2002) Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density. J Clin Densitom 5:152–158

    Article  Google Scholar 

  37. Pasco JA, Kotowicz MA, Henry MH, et al (2002) Statin use, bone mineral density, and fracture. Arch Intern Med 162:537–540

    Article  CAS  PubMed  Google Scholar 

  38. Rejnmark L, Buus NH, Vestergaard P, et al (2002) Statins decrease bone turnover in postmenopausal women: a cross sectional study. Eur J Clin Invest 32:581–589

    Article  CAS  PubMed  Google Scholar 

  39. Ray WA, Daugherty JR, Griffin MR (2002) Lipid lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8:276–279

    Article  CAS  PubMed  Google Scholar 

  40. Watanabe S, Fukumoto S, Takeuchi Y, et al (2001) Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584–587

    Article  CAS  PubMed  Google Scholar 

  41. Reid IR, Hague W, Emberson J, et al (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 357:509–512

    Article  CAS  PubMed  Google Scholar 

  42. Pederson TR, Kjekshus J (2000) Statin drugs and the risk of fracture. JAMA 284:1921–1922

    Article  Google Scholar 

  43. Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on bone remodeling. Osteoporos Int 12:380–384

    Google Scholar 

  44. Hsia J, Morse M, Levin V (2002) Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial. BMC Musculoskelet Disord 3:1–5

    Google Scholar 

  45. Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr Metab Cardiovasc Dis 11:84–87

    CAS  PubMed  Google Scholar 

  46. Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L (2004) Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 19:737–744

    CAS  PubMed  Google Scholar 

  47. Looker AC, Bauer DC, Chestnut CH, et al (2000) Clinical use of biochemical bone markers of bone remodeling: current status and future direction. Osteoporos Int 11:467–480

    Article  CAS  PubMed  Google Scholar 

  48. Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 [10 Suppl]:s1–s27

  49. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26–37

    Google Scholar 

  50. Sugiyama M, Kodama T, et al (2000) Compactin and simvastatin, but not pravastatin, induce bone-morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:699–692

    Article  PubMed  Google Scholar 

  51. Hennessy S, Strom BL (2001) Statins and fracture risk. JAMA 285:1888–1889

    Article  CAS  PubMed  Google Scholar 

  52. Marshall D, Johnell O (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259

    CAS  PubMed  Google Scholar 

  53. Osteoporosis among estrogen-deficient women—United States, 1988–1994. MMWR Morb Mortal Wkly Rep 47:969–973

  54. Fisher ES, Baron JA, Malenka DJ, et al (1991) Hip fracture incidence and mortality in New England. Epidemiology 2:116–122

    CAS  PubMed  Google Scholar 

  55. Marottoli RA, Berkman LF, Cooney LM (1992) Decline in physical function following hip fracture. J Am Geriatr Soc 40:861–866

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tripler Army Medical Center, Honolulu, Hawaii, USA

    Christos Hatzigeorgiou

  2. Medicine-EDP, 4301 Jones Bridge Road, Bethesda, Maryland, MD 20814, USA

    Jeffrey L. Jackson

  3. Uniformed Services University, Bethesda, Maryland, USA

    Jeffrey L. Jackson

Authors
  1. Christos Hatzigeorgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey L. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The opinions in this manuscript reflect those of the authors and should not be construed, in any way, to reflect those of the Army or Department of Defense

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hatzigeorgiou, C., Jackson, J.L. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16, 990–998 (2005). https://doi.org/10.1007/s00198-004-1793-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-004-1793-0

Keywords

Search

Navigation